Belviq FDA Approval History
Last updated by Judith Stewart, BPharm on May 4, 2021.
FDA Approved: Yes (Discontinued) (First approved June 27, 2012)
Brand name: Belviq
Generic name: lorcaserin
Dosage form: Tablets
Company: Arena Pharmaceuticals, Inc.
Treatment for: Anti-obesity Medications for Weight Loss (Obesity/Overweight)
Belviq (lorcaserin) is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese, or overweight and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Development timeline for Belviq
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.